<?xml version="1.0" encoding="UTF-8"?>
<p id="Par39">Viral RNA synthesis blockers also have potential. Remdesivir has broad-spectrum activity against MERS-CoV and SARS-CoV in cell cultures and animal models and is currently in clinical development for the treatment of Ebola virus disease.
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>,
  <xref ref-type="bibr" rid="CR125">125</xref>
 </sup> It was also reported positively based on a patient with SARS-CoV-2 infection in the US,
 <sup>
  <xref ref-type="bibr" rid="CR126">126</xref>
 </sup> and another study showed that it was able to inhibit the virus.
 <sup>
  <xref ref-type="bibr" rid="CR117">117</xref>
 </sup> Ribavirin is often used to treat SARS and MERS, but it is uncertain whether it is potent enough against COVID-19.
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>,
  <xref ref-type="bibr" rid="CR108">108</xref>
 </sup> Regardless, when used alone, ribavirin has minimal activity against SARS-CoV and may cause strong side effects. It is often used together with corticosteroids.
 <sup>
  <xref ref-type="bibr" rid="CR14">14</xref>,
  <xref ref-type="bibr" rid="CR127">127</xref>
 </sup> A preclinical study of galidesivir (BCX4430), an adenosine analog, revealed antiviral activity against SARS-CoV and MERS-CoVCoV.
 <sup>
  <xref ref-type="bibr" rid="CR115">115</xref>
 </sup> A study of favipiravir (T-705), a guanine analog, proved its activity against SARS-CoV-2, and randomized trials of favipiravir plus interferon-Î± (ChiCTR2000029600), and favipiravir plus baloxavir marboxil (ChiCTR2000029544) are in progress.
 <sup>
  <xref ref-type="bibr" rid="CR34">34</xref>
 </sup>
</p>
